Lipid-Targeted Atherosclerotic Risk Reduction in Older Adults: A Review.
Lauren J HassenSteven R ScarfoneMichael Wesley MilksPublished in: Geriatrics (Basel, Switzerland) (2022)
Aggressive lipid-lowering lifestyle modifications and pharmacologic therapies are the cornerstones of the primary and secondary prevention of atherosclerotic cardiovascular disease events. While statins are highly effective, inexpensive, and generally well-tolerated medications, many clinicians and patients express uncertainty regarding the necessity of statin treatment in older adults. Citing concerns such as polypharmacy, muscle symptoms, and even potential cognitive changes with statins, many patients and health care providers elect to de-intensify or discontinue statin therapy during the process of aging. A lack of clear representation of older individuals in many clinical trials and practice guidelines may contribute to the ambiguity. However, the recently prevailing data and practice patterns supporting the benefits, safety, and tolerability of a variety of lipid-lowering therapeutics in older adults are discussed here, with particular mention of a potential protective effect from incident dementia among a statin-treated geriatric population and an admonishment of the historical concept of "too-low" low-density lipoprotein cholesterol (LDL-C) levels.
Keyphrases
- cardiovascular disease
- end stage renal disease
- physical activity
- healthcare
- newly diagnosed
- clinical trial
- chronic kidney disease
- ejection fraction
- prognostic factors
- type diabetes
- coronary artery disease
- primary care
- emergency department
- stem cells
- fatty acid
- depressive symptoms
- cardiovascular events
- randomized controlled trial
- palliative care
- weight loss
- machine learning
- electronic health record
- deep learning
- skeletal muscle
- human health
- drug delivery
- mesenchymal stem cells
- risk assessment
- middle aged
- patient reported
- quality improvement